Integrated Diagnostics Holdings (LSE:IDHC) 3-Year EBITDA Growth Rate : -19.00% (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Integrated Diagnostics Holdings 3-Year EBITDA Growth Rate?

Integrated Diagnostics Holdings's EBITDA per Share for the three months ended in Jun. 2023 was $0.01.

During the past 12 months, Integrated Diagnostics Holdings's average EBITDA Per Share Growth Rate was -21.60% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -19.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -0.30% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 6.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Integrated Diagnostics Holdings was 53.80% per year. The lowest was -19.00% per year. And the median was -0.35% per year.

Competitive Comparison of Integrated Diagnostics Holdings's 3-Year EBITDA Growth Rate

For the Diagnostics & Research subindustry, Integrated Diagnostics Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Integrated Diagnostics Holdings's 3-Year EBITDA Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Integrated Diagnostics Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Integrated Diagnostics Holdings's 3-Year EBITDA Growth Rate falls into.

Integrated Diagnostics Holdings 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Integrated Diagnostics Holdings (LSE:IDHC) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Integrated Diagnostics Holdings 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Integrated Diagnostics Holdings's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Integrated Diagnostics Holdings (LSE:IDHC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Integrated Diagnostics Holdings PLC (LSE:IDHC) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

IDGXF:USA IDHCl:UK IDHC.CA:Egypt 8I8:Germany

Address

12 Castle Street, Saint Helier, JEY, JE2 3RT

Website

https://www.idhcorp.com

Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider. It is a fully integrated diagnostics service provider operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segment- Contract Segment and Walk-in Segment. It derives majority of its revenue from services offered in Egypt.

Integrated Diagnostics Holdings (LSE:IDHC) Headlines

No Headlines